Answers are grounded in this paper and cite their sources.
To the Editor: Thalidomide has recently been shown to be effective for the treatment of refractory myeloma.1,2 We report a case of life-threatening toxic epidermal necrolysis with the combined use of thalidomide and dexamethasone in a patient with previously untreated myeloma. A 64-year-old man with newly diagnosed myeloma presented with multiple lytic bone lesions, anemia, and hypercalcemia, with a serum IgA-lambda monoclonal protein level of 41 g per liter and 90 percent plasma cells in the bone marrow. After obtaining informed consent, we initiated treatment with thalidomide and dexamethasone as part of an ongoing phase 2 trial. The patient . . .
No takes yet. Share an insight, caveat, or question.
Rajkumar et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: